Erste Group Bank Predicts Stronger Earnings for Novartis

Novartis AG (NYSE:NVS) – Stock analysts at Erste Group Bank lifted their FY2026 earnings per share estimates for Novartis in a research report issued on Monday, July 27th. Erste Group Bank analyst H. Engel now anticipates that the company will post earnings per share of $9.09 for the year, up from their previous estimate of $8.90. The consensus estimate for Novartis’ current full-year earnings is $8.82 per share. Erste Group Bank also issued estimates for Novartis’ FY2027 earnings at $9.82 EPS.

Novartis (NYSE:NVS) last issued its quarterly earnings data on Tuesday, June 30th. The company reported $2.41 earnings per share (EPS) for the quarter. The business had revenue of $14.95 billion for the quarter. Novartis had a return on equity of 38.56% and a net margin of 23.29%.

NVS has been the topic of several other research reports. Weiss Ratings restated a “buy (b)” rating on shares of Novartis in a report on Friday, July 24th. Citigroup reaffirmed a “buy” rating on shares of Novartis in a research note on Wednesday, July 22nd. Seven equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Novartis presently has a consensus rating of “Hold” and an average target price of $141.20.

Novartis Price Performance

Shares of Novartis stock opened at $158.45 on Friday. The stock has a market cap of $302.35 billion, a price-to-earnings ratio of 23.90, a price-to-earnings-growth ratio of 2.73 and a beta of 0.45. The company has a debt-to-equity ratio of 0.89, a quick ratio of 0.67 and a current ratio of 0.86. The stock has a 50 day moving average price of $152.58 and a 200-day moving average price of $152.70. Novartis has a one year low of $112.34 and a one year high of $170.46.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of NVS. Arlington Trust Co LLC purchased a new stake in shares of Novartis in the fourth quarter worth approximately $25,000. Archer Investment Corp boosted its holdings in Novartis by 93.0% during the 1st quarter. Archer Investment Corp now owns 166 shares of the company’s stock valued at $25,000 after acquiring an additional 80 shares during the period. Evolution Wealth Management Inc. grew its position in Novartis by 552.0% in the 2nd quarter. Evolution Wealth Management Inc. now owns 163 shares of the company’s stock valued at $26,000 after acquiring an additional 138 shares during the last quarter. Atlatl Advisers LLC bought a new position in Novartis in the 2nd quarter valued at $26,000. Finally, CrossGen Wealth LLC purchased a new stake in Novartis in the fourth quarter worth $28,000. Hedge funds and other institutional investors own 13.12% of the company’s stock.

Novartis Company Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.